Ronac Mamtani, MD, MSCE
Medical Oncology
Accepting new patients
Sees patients age 18 and up
Abramson Cancer Center Perelman 2nd Floor West
Make an appointmentCall 215-615-5858
Headshot of Ronac Mamtani, MD, MSCE
Penn Medicine Provider

About me

  • Section Chief, Genitourinary Cancers, Hematology-Oncology
  • David J. Vaughn MD Professorship in GU Oncology

Education and training

  • Medical School: SUNY Stony Brook School of Medicine
  • Residency: NewYork-Presbyterian/Weill Cornell Medical Center
  • Fellowship: University of Pennsylvania Health System

What my patients think about me

Average Rating

214 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

February 2026
i have complete confidence in the dr's knowledge and professional approach.
February 2026
friendly, informative, excellent!
February 2026
great interaction with our physician
February 2026
dr. mamtani spent time explaining everything

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Dr. Mamtani is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Squires P, Cook EE, Song Y, Wang CY, Zhang A, Seshasayee SM, Rogiers A, Li H, Mamtani R. Treatment Patterns, Disease Recurrence, and Overall Survival in Patients With Muscle-Invasive Bladder Cancer After Radical Cystectomy: A Population-Level Claims-Based Analysis , Clin Genitourin Cancer: 2026

Chow RD, Sedhom R, Mamtani R. Reduced-Dose Enfortumab Vedotin, Treatment Continuity, and Survival in Urothelial Cancer , JAMA Oncol: 2025

Litt HK, Mamtani R, Chow RD. Outcomes of enfortumab vedotin plus pembrolizumab in patients with advanced urothelial cancer and severe renal dysfunction , Urol Oncol: 2025

Kong AM, Andrean D, Khan S, Choi J, Mamtani R, Parikh R, Jaksa A, Campbell U. Considerations for emulations of randomized controlled trials using real-world data: learnings from an emulation of MONALEESA-2 , J Comp Eff Res: 2025

Chow RD, Mamtani R. Assessment of synergistic vs. independent drug activity for enfortumab vedotin and pembrolizumab in untreated advanced urothelial carcinoma , Urol Oncol, 43(10): 2025,597

Meng Y, Zhang S, Aout M, Babcock A, Li H, Lai Y, Brand-Wiita S, Notinger S, Bavle A, Mamtani R. Cost-effectiveness of enfortumab vedotin plus pembrolizumab as a first-line treatment of locally advanced or metastatic urothelial carcinoma in the United States , J Med Econ: 2025

Squires P, Cook EE, Song Y, Wang CY, Jiang AX, Zhang A, Seshasayee SM, Rogiers A, Li H, Mamtani R. Real-world economic burden of disease recurrence in patients with muscle-invasive bladder cancer: A population-level claims-based analysis , J Manag Care Spec Pharm: 2025

Chow RD, Mamtani R. Association Between Early on-Treatment Weight Loss With Enfortumab Vedotin Plus Pembrolizumab and Survival in Advanced Urothelial Carcinoma , Clin Genitourin Cancer: 2025

Parikh RB, Ulloa-Pérez E, Kurian M, Hubbard R, Joffe S, Lynch HF, Mamtani R. Prescribing Changes After Accelerated vs Regular Approval of Oncology Therapies , JAMA Netw Open, 8(7): 2025,e2520726

Lian Y, Voruganti T, Lu J, Long Q, Mamtani R. Survival Trends in Urothelial Cancer Before and After ICIs and Antibody Drug Conjugates , JAMA Netw Open, 8(7): 2025,e2519524